Full-Time
Director of Marketing
Cala Health
51-200 employees
FDA-approved wearable tremor therapy device
Compensation Overview
$170k - $220k/yr
No H1B Sponsorship
San Francisco, CA, USA
In Person
Must be authorized to work in the United States; no visa sponsorship.
 Growth & Marketing (1) |
|---|
- 10+ years of marketing experience in FDA regulated product management and commercialization - downstream marketing in medical device, diagnostics or related field. DME experience a plus.
- Bachelor’s degree required in Science or Engineering with MBA preferred.
- Strong strategic, analytical thinking, people leadership, and cross-functional stakeholder influence.
- Proven ability to think strategically and translate vision into actionable plans and results.
- Comfortable navigating ambiguity and driving results in a fast-paced, evolving landscape.
- Outstanding communication, organization collaboration.
- Ability to travel up to 25% of the time.
- Drive execution and alignment of commercial strategic plan to hit revenue, profitability, and company objectives.
- Define and shape go-to-market strategy and commercialization initiatives from product to process and support, including customer journeys.
- Drive awareness, market adoption, identify growth opportunities, and gain market insights to reflect patient and provider needs and alignment with strategic goals.
- Lead Commercial Launch plans (positioning, messaging, customer targeting, branding, evidence strategy, KOL strategy, metrics etc.)
- Manage integrated marketing channels (digital, conferences, social media, etc.) and vendors.
- Leading, coaching and developing a team of marketing professionals
- Gather new entrant intel and lead competitive action / response plans
- Spending time in the field to gain market and customer insights and build relationships with sales leaders and key physicians to drive education, market adoption and innovation.
- Define KPIs and measures that define customer preference and retention
Cala Health develops the Cala kIQ System, a physician-prescribed wearable that treats hand tremors from essential tremor and Parkinson’s disease using TAPS therapy. TAPS is a non-invasive electrical stimulation of skin nerves delivered via the wearable during roughly 40-minute sessions to reduce tremors. The device collects patient data to help patients and doctors monitor progress and tailor care, blending non-drug therapy with existing medications. It differentiates itself by FDA-approved, physician-prescribed, non-invasive, data-driven therapy that complements medical treatment, with the goal of improving daily tremor management and supporting measurable clinical outcomes.
Company Size
51-200
Company Stage
Growth Equity (Venture Capital)
Total Funding
$298.3M
Headquarters
San Mateo, California
Founded
2014
Simplify's Take
What believers are saying
- FDA cleared Cala kIQ Plus on April 15, 2026, with adaptive calibration boosting efficacy.
- $50M funding from Trinity Capital and Niterra Ventures fuels commercial expansion in 2025.
- Medicare coverage in all 50 states since 2024 expands reimbursable patient access.
What critics are saying
- Cala Trio's ultrasound neuromodulation captures 20-30% ET market share within 12 months.
- Medtronic Percept PC DBS diverts PD patients, slashing Cala's revenue by 40% in 6 months.
- PROSPECT follow-up shows 25% adherence, triggering VA and Medicare clawbacks in 6 months.
What makes Cala Health unique
- Cala kIQ Plus uses TAPS technology for personalized transcutaneous afferent patterned stimulation.
- Only FDA-cleared wearable delivers effective action hand tremor therapy for ET and PD.
- Device worn like wristwatch alternates stimulation between median and radial nerves.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Cala Health who can refer or advise you
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -1%2 year growth
↓ -1%In psychedelics and neuroscience... Cala Health announced FDA clearance of its next-generation Cala kIQ Plus wearable, a new upgrade to its existing neurostimulation platform for essential tremor and Parkinson's disease. The device builds on its TAPS (transcutaneous afferent patterned stimulation) technology, adding new therapy modes and adaptive calibration designed to improve tremor control and personalize treatment delivery. The updated system allows patients greater control over when and how therapy is delivered, while early clinical data suggest improved response rates and broader efficacy, including bilateral tremor improvement. Check it out: https://www.prnewswire.com/news-releases/cala-announces-fda-clearance-of-its-next-generation-taps-therapy-wearable-device-for-essential-tremor-and-parkinsons-disease-302742780.html. Compass Pathways announced a U.S. grant program to fund the development of training programs for healthcare providers ahead of a potential commercial launch of its psilocybin-based therapy, COMP360. COMP360, a synthetic psilocybin therapy for treatment-resistant depression. The company is now positioning for a potential filing and approval timeline. The grant program is designed to ensure providers are trained, operationally ready, and aligned with regulatory standards, which is critical for a therapy that requires supervised administration rather than traditional prescribing. Here's more: https://ir.compasspathways.com/News-Events-/news/news-details/2026/Compass-Pathways-Announces-U-S-Grant-Program-for-the-Creation-of-Post-Approval-COMP360-Provider-Training/default.aspx. Roche received CE marking in Europe for its Elecsys Neurofilament Light Chain (NfL) blood test, allowing its commercial use across the region. The test measures levels of a protein released when nerve cells are damaged, offering a direct, blood-based signal of neurological activity instead of relying solely on periodic MRIs or symptom tracking. NfL is also not disease-specific, with elevated levels seen across multiple neurodegenerative conditions, including Alzheimer's and traumatic brain injury. That positions the test as part of a broader move toward blood-based biomarkers as a core tool in neurology, rather than a single-use diagnostic. Check it out: https://jlsfund.substack.com/p/a-simple-blood-draw-could-replace Did you know? Did you know that earlier attention deficit-hyperactivity disorder (ADHD) diagnosis could be linked to a lower probability of school dropout? A recent study published in JAMA Psychiatry looked at when people are first diagnosed with ADHD and how that timing affects their long-term outcomes. Researchers found that individuals diagnosed earlier were more likely to perform better in school, continue their education, and avoid dropping out compared to those diagnosed later in adolescence. Certainly, it makes sense that early diagnosis could shape someone's progress through school and into adulthood. After all, if the condition is identified earlier, there's more time to receive support. That being said, this particular study offers real data to support that thesis. It tracked over 500,000 individuals and found that those diagnosed earlier (typically in childhood) had better grades, were more likely to pursue academic paths, and were less likely to drop out of school compared to those diagnosed later in adolescence. The takeaway is pretty straightforward. ADHD doesn't suddenly appear in high school; it's usually there earlier. But if it's not identified, students miss out on support during the years when it matters most. By the time a diagnosis happens later (often around ages 14 to 16), academic struggles may already be entrenched, and the data show dropout risk can rise significantly, in some cases approaching 30%.
Niterra Ventures today announced its participation in the oversubscribed $50M funding round for Cala, the bioelectronic medicine leader. Recognized by Fast C...
Niterra Ventures participated in an oversubscribed $50 million growth financing round for Cala Health, a leader in bioelectronic medicine. Cala's FDA-cleared, noninvasive devices provide relief for hand tremors in essential tremor and Parkinson's disease. The funding will help Cala scale operations and expand sales and marketing. Cala's TAPS therapy, which received Medicare coverage in 2024, has been validated in multiple studies, showing effectiveness in reducing tremor severity.
Niterra Ventures participates in oversubscribed $50M growth financing round for Cala. October 20, 2025. SANTA CLARA, Calif.-(BUSINESS WIRE)-Niterra Ventures announced its participation in the oversubscribed $50M funding round for Cala, the bioelectronic medicine leader. Recognized by Fast Company's list of the Most Innovative Medical Device Companies in 2025, Cala's products are the only FDA-cleared, clinically validated, noninvasive devices for the relief of action hand tremors in essential tremor and Parkinson's disease. Nearly 10 million Americans experience essential tremor and are unable to control their hands to complete everyday tasks. The Cala kIQ(TM) System with TAPS(TM) therapy provides transcutaneous afferent patterned stimulation to reduce tremor severity for daily activities of living such as eating, drinking, writing and self care. The Cala wearable device delivers individualized stimulation to counteract tremor noninvasively, through the nerves that run from your wrist to your brain. In 2024, Cala's TAPS therapy received Medicare coverage in all 50 states. "Cala's unique approach to managing essential tremors represents a platform technology that can pave the way to meaningfully benefit many people living with different chronic conditions, now and in the future," said Deanna Harshbarger, CEO of Cala Health. "Niterra Ventures' investment opens commercialization opportunities and enables us to scale our team to drive broader adoption and engagement, helping more people live better lives." Cala TAPS Therapy has been validated across multiple clinical studies in over 2,000 patients. Most recently during the International Congress of Parkinson's Disease and Movement Disorders (MDS) Conference, Cala announced results that reinforced the brain-based mechanism of TAPS(TM) therapy through PET imaging and the publication of a groundbreaking study in the journal Brain Stimulation. This study provides new evidence that non-invasive Cala TAPS(TM) therapy reduces tremor in patients with essential tremor (ET) by directly modulating neural activity in the brain. Earlier this year, Cala announced that analysis of data from the multi-center PROSPECT study (263 patients) indicates consistent usage of Cala TAPS Therapy reduces underlying tremor severity. With this investment, Cala will scale commercial operations and expand its sales and marketing efforts to educate both patients and healthcare providers about this innovative therapy. "Niterra Ventures supports opportunities that improve life quality through cutting-edge technologies," said Dirk Schapeler, president of Niterra Ventures. "Cala's commitment to transforming the standard of care for patients and clinicians through customer-centric innovation shows in its success in demonstrating clinical value and gaining Medicare support. Our investment in Cala aligns with our mission for utilizing new technologies and therapies that improve chronic disease management and enhance a person's overall quality of life." As a part of its effort in healthcare, Niterra Ventures Company is investing in technology detecting and assessing chronic conditions, including related to cardiology, oncology, neurology and hypertension. About Cala(R) Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies. Cala Health's products are the only FDA-cleared, clinically validated noninvasive devices for the relief of hand tremors in essential tremor and Parkinson's disease. New therapies are under development in neurology, cardiology, and other chronic condition. Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. The Cala(TM) kIQ device is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor. The Cala kIQ device is indicated to aid in the temporary relief of postural and kinetic hand tremor symptoms that impact some activities of daily living in the treated hand following stimulation in adults with Parkinson's disease. The Cala kIQ device delivers Transcutaneous Afferent Patterned Stimulation (TAPS) therapy. About Niterra Ventures Company Niterra Ventures Company is the venture arm of Niterra Co., Ltd. (formerly NGK Spark Plug Co., Ltd.). Niterra, a coined word combining the Latin words "niteo" (shine) and "terra" (Earth), was introduced in April 2023 to express the reborn company's commitment to sustainability through an evolving portfolio focused on ceramics and beyond. Under the corporate message "IGNITE YOUR SPIRIT," Niterra is expanding into the growth fields of mobility, healthcare, environment and energy, and communications. The company's consolidated revenues in fiscal 2022 (to March 2023) totaled 562.6 billion yen (4,167 million USD). Niterra has 33 bases in Japan and 59 overseas, and more than 16,000 employees worldwide. The Alliance of Chief Executives is an active community of business leaders that focuses on deep strategic exchanges, challenging existing assumptions and generating fresh ideas. Contact Alliance of Chief Executives, LLC. * 925-942-2400 Office * 925-956-4424 Fax * Email: [email protected] The Alliance of Chief Executives is an active community of business leaders that focuses on deep strategic exchanges, challenging existing assumptions and generating fresh ideas.
Tala Health, a subsidiary of Titan Holdings, has emerged from stealth with a $100 million seed round, valuing the company at $1.2 billion. Partnering with major insurers, Tala Health aims to revolutionize healthcare by using AI to provide 24/7 on-demand care, reducing wait times and improving patient outcomes. The funding will enhance AI and clinical teams, product development, and market efforts. Investors include Sofreh Capital and Dr. P. Roy Vagelos.